Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
0.8200
-0.0487 (-5.61%)
At close: Apr 4, 2025, 4:00 PM
0.8001
-0.0199 (-2.43%)
After-hours: Apr 4, 2025, 7:50 PM EDT

Moleculin Biotech Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
-21.76-29.77-29.03-15.89-17.36
Upgrade
Depreciation & Amortization
0.130.130.130.160.2
Upgrade
Loss (Gain) From Sale of Assets
----0.01
Upgrade
Stock-Based Compensation
1.731.982.282.371.68
Upgrade
Other Operating Activities
-4.182.45-1.24-6.63-2.26
Upgrade
Change in Accounts Payable
-0.470.40.730.24-1.02
Upgrade
Change in Other Net Operating Assets
0.71.22-0.510.80.98
Upgrade
Operating Cash Flow
-23.86-23.59-27.64-18.95-17.77
Upgrade
Capital Expenditures
-0.01-0.12-0.07-0.02-0.38
Upgrade
Sale of Property, Plant & Equipment
----0
Upgrade
Investing Cash Flow
-0.01-0.12-0.07-0.02-0.37
Upgrade
Issuance of Common Stock
4.664.17-74.7522.57
Upgrade
Repurchase of Common Stock
-0.03-0.03-0.02-0.02-0.02
Upgrade
Financing Cash Flow
4.644.14-0.0274.7222.55
Upgrade
Foreign Exchange Rate Adjustments
-0.03-0.02-0.03-0.020.03
Upgrade
Net Cash Flow
-19.27-19.6-27.7655.734.44
Upgrade
Free Cash Flow
-23.88-23.72-27.71-18.97-18.15
Upgrade
Free Cash Flow Per Share
-6.93-12.00-14.53-10.59-27.65
Upgrade
Cash Income Tax Paid
----0.02
Upgrade
Levered Free Cash Flow
-14.36-14.6-16.09-10.17-10.77
Upgrade
Unlevered Free Cash Flow
-14.36-14.6-16.09-10.17-10.77
Upgrade
Change in Net Working Capital
-0.33-1.74-0.32-1.16-0.06
Upgrade
Updated Mar 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q